Identification

Name
Doxacurium
Commonly known or available as Doxacurium chloride
Accession Number
DB01135  (APRD00934, DB01334)
Type
Small Molecule
Groups
Approved
Description

Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Doxacurium chlorideM78TVM3G5Z83348-52-1APADFLLAXHIMFU-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NuromaxLiquid1 mgIntravenousAbbvie1992-12-312012-11-03Canada
Categories
UNII
P40015Y3WW
CAS number
106791-39-3
Weight
Average: 1035.2223
Monoisotopic: 1034.535134458
Chemical Formula
C56H78N2O16
InChI Key
GBLRQXKSCRCLBZ-UHFFFAOYSA-N
InChI
InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2
IUPAC Name
6,7,8-trimethoxy-2-methyl-2-(3-{[4-oxo-4-(3-{6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propoxy)butanoyl]oxy}propyl)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
SMILES
COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC

Pharmacology

Indication

Used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.

Pharmacodynamics

Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine.

Mechanism of action

Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission (non-depolarizing). This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 0.11-0.43 L/kg [Healthy Young Adult Patients]
  • 0.17-0.55 L/kg [Kidney Transplant Patients]
  • 0.17-0.35 L/kg [Liver Transplant Patients]
Protein binding

Approximately 30%.

Metabolism

In vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.

Route of elimination

In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.

Half life

99 minutes in normal healthy adults.

Clearance
  • 2.66 mL/min/kg [Healthy Young Adult Patients]
  • 1.23 mL/min/kg [Kidney Transplant Patients]
  • 2.3 mL/min/kg [Liver Transplant Patients]
  • 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)]
  • 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)]
Toxicity

Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinDoxacurium chloride may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinDoxacurium chloride may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineAgmatine may increase the neuromuscular blocking activities of Doxacurium.Experimental, Investigational
AmikacinThe therapeutic efficacy of Doxacurium can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneAmiodarone may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Doxacurium.Approved
ApramycinApramycin may increase the respiratory depressant activities of Doxacurium chloride.Experimental, Vet Approved
AranidipineAranidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
ArbekacinArbekacin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Investigational
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Doxacurium.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Doxacurium.Approved
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Doxacurium chloride.Experimental
BencyclaneBencyclane may increase the neuromuscular blocking activities of Doxacurium.Experimental
BenidipineBenidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Doxacurium.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Doxacurium.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Doxacurium.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Doxacurium.Approved, Withdrawn
BioallethrinBioallethrin may increase the neuromuscular blocking activities of Doxacurium.Approved, Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational
Botulinum Toxin Type BDoxacurium chloride may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxacurium.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Doxacurium.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Doxacurium.Approved, Investigational
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Doxacurium.Investigational
CaroverineCaroverine may increase the neuromuscular blocking activities of Doxacurium.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Doxacurium.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxacurium.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Doxacurium.Approved, Investigational
ClevidipineClevidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
ClindamycinThe therapeutic efficacy of Doxacurium can be increased when used in combination with Clindamycin.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Doxacurium.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Vet Approved
CyclandelateCyclandelate may increase the neuromuscular blocking activities of Doxacurium.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxacurium.Approved
CyclosporineThe therapeutic efficacy of Doxacurium can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinDoxacurium chloride may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineDarodipine may increase the neuromuscular blocking activities of Doxacurium.Experimental
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DeslanosideDoxacurium chloride may increase the arrhythmogenic activities of Deslanoside.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Doxacurium is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxacurium.Approved
DexniguldipineDexniguldipine may increase the neuromuscular blocking activities of Doxacurium.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Doxacurium is combined with Dextromethorphan.Approved
DexverapamilDexverapamil may increase the neuromuscular blocking activities of Doxacurium.Experimental
DibekacinDibekacin may increase the respiratory depressant activities of Doxacurium chloride.Experimental
DigitoxinDoxacurium chloride may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinDoxacurium chloride may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Doxacurium chloride may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Doxacurium chloride.Investigational, Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxacurium.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doxacurium.Approved, Investigational
DotarizineDotarizine may increase the neuromuscular blocking activities of Doxacurium.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxacurium.Approved, Vet Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
EmopamilEmopamil may increase the neuromuscular blocking activities of Doxacurium.Experimental
EperisoneEperisone may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational
EthanolDoxacurium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideEthosuximide may increase the neuromuscular blocking activities of Doxacurium.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxacurium.Approved
FelodipineFelodipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Doxacurium.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxacurium.Approved, Illicit, Investigational, Vet Approved
Fish oilFish oil may increase the neuromuscular blocking activities of Doxacurium.Approved, Nutraceutical
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Doxacurium.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Doxacurium is combined with Fluoxetine.Approved, Vet Approved
FluspirileneFluspirilene may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Doxacurium.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Doxacurium is combined with Fluvoxamine.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Doxacurium chloride.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Doxacurium.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
GallopamilGallopamil may increase the neuromuscular blocking activities of Doxacurium.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Doxacurium chloride.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Doxacurium chloride.Experimental
GitoformateDoxacurium chloride may increase the arrhythmogenic activities of Gitoformate.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Doxacurium.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Doxacurium.Approved, Vet Approved
HydrocodoneDoxacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxacurium.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Doxacurium chloride.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Doxacurium.Approved
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Doxacurium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Doxacurium chloride.Experimental
IsradipineIsradipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Investigational, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Doxacurium.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
Lanatoside CDoxacurium chloride may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
LevetiracetamLevetiracetam may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Doxacurium.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Doxacurium.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Doxacurium chloride.Experimental
LomerizineLomerizine may increase the neuromuscular blocking activities of Doxacurium.Experimental
LoperamideLoperamide may increase the neuromuscular blocking activities of Doxacurium.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Doxacurium.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Doxacurium chloride can be increased when used in combination with Lorpiprazole.Approved
Magnesium carbonateThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
Magnesium sulfateThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium Trisilicate.Approved
ManidipineManidipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Doxacurium.Approved
MentholMenthol may increase the neuromuscular blocking activities of Doxacurium.Approved
MethsuximideMethsuximide may increase the neuromuscular blocking activities of Doxacurium.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinDoxacurium chloride may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetoclopramideThe therapeutic efficacy of Doxacurium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MibefradilMibefradil may increase the neuromuscular blocking activities of Doxacurium.Investigational, Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Doxacurium chloride.Experimental
MinocyclineMinocycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Doxacurium.Investigational
NeamineNeamine may increase the respiratory depressant activities of Doxacurium chloride.Experimental
NeomycinThe therapeutic efficacy of Doxacurium can be increased when used in combination with Neomycin.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Investigational
NicardipineNicardipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
NifedipineNifedipine may increase the neuromuscular blocking activities of Doxacurium.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Doxacurium.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Doxacurium.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
NimesulideNimesulide may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Doxacurium.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
NylidrinNylidrin may increase the neuromuscular blocking activities of Doxacurium.Approved
OleandrinDoxacurium chloride may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Doxacurium.Approved
OtiloniumOtilonium may increase the neuromuscular blocking activities of Doxacurium.Experimental, Investigational
OuabainDoxacurium chloride may increase the arrhythmogenic activities of Ouabain.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxacurium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxacurium.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational, Vet Approved
ParomomycinThe therapeutic efficacy of Doxacurium can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Doxacurium is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the neuromuscular blocking activities of Doxacurium.Experimental
PeruvosideDoxacurium chloride may increase the arrhythmogenic activities of Peruvoside.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doxacurium.Approved, Investigational
PinaveriumPinaverium may increase the neuromuscular blocking activities of Doxacurium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Doxacurium chloride.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Doxacurium can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleDoxacurium may increase the sedative activities of Pramipexole.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Prednisolone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Doxacurium can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Doxacurium.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxacurium.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Doxacurium.Approved, Investigational
ProscillaridinDoxacurium chloride may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Doxacurium is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Doxacurium chloride.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Doxacurium is combined with Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Doxacurium.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Doxacurium chloride.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Doxacurium is combined with Rizatriptan.Approved
RopiniroleDoxacurium may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxacurium.Approved, Investigational
SeletracetamSeletracetam may increase the neuromuscular blocking activities of Doxacurium.Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Doxacurium chloride.Investigational
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Doxacurium.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Doxacurium is combined with Sumatriptan.Approved, Investigational
TerodilineTerodiline may increase the neuromuscular blocking activities of Doxacurium.Experimental
TetracyclineThe therapeutic efficacy of Doxacurium can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Doxacurium.Investigational
TetrandrineTetrandrine may increase the neuromuscular blocking activities of Doxacurium.Experimental
TobramycinTobramycin may increase the respiratory depressant activities of Doxacurium chloride.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxacurium.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Doxacurium.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved, Vet Approved
TrimebutineTrimebutine may increase the neuromuscular blocking activities of Doxacurium.Approved
TrimethadioneTrimethadione may increase the neuromuscular blocking activities of Doxacurium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Doxacurium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Doxacurium.Approved, Investigational
VancomycinThe therapeutic efficacy of Doxacurium can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Doxacurium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Doxacurium is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Doxacurium.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Doxacurium.Investigational
WIN 55212-2WIN 55212-2 may increase the neuromuscular blocking activities of Doxacurium.Experimental
ZiconotideZiconotide may increase the neuromuscular blocking activities of Doxacurium.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Doxacurium is combined with Zolmitriptan.Approved, Investigational
ZolpidemDoxacurium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the neuromuscular blocking activities of Doxacurium.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Martinez EA, Wooldridge AA, Hartsfield SM, Mealey KL: Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs. Vet Surg. 1998 May-Jun;27(3):279-83. [PubMed:9605239]
External Links
Human Metabolome Database
HMDB0015266
KEGG Drug
D00760
KEGG Compound
C07549
PubChem Compound
5284551
PubChem Substance
46506733
ChemSpider
54249
ChEBI
59819
ChEMBL
CHEMBL1237123
Therapeutic Targets Database
DAP000350
PharmGKB
PA164744927
RxList
RxList Drug Page
Wikipedia
Doxacurium_chloride
ATC Codes
M03AC07 — Doxacurium chloride

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous1 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.02e-05 mg/mLALOGPS
logP3.44ALOGPS
logP-2.5ChemAxon
logS-7.1ALOGPS
pKa (Strongest Acidic)18.41ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area163.36 Å2ChemAxon
Rotatable Bond Count29ChemAxon
Refractivity302.15 m3·mol-1ChemAxon
Polarizability113.56 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9919
Blood Brain Barrier+0.9419
Caco-2 permeable+0.6166
P-glycoprotein substrateSubstrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.5903
P-glycoprotein inhibitor IIInhibitor0.6915
Renal organic cation transporterNon-inhibitor0.5328
CYP450 2C9 substrateNon-substrate0.8563
CYP450 2D6 substrateNon-substrate0.7468
CYP450 3A4 substrateSubstrate0.6802
CYP450 1A2 substrateNon-inhibitor0.9149
CYP450 2C9 inhibitorNon-inhibitor0.963
CYP450 2D6 inhibitorNon-inhibitor0.9124
CYP450 2C19 inhibitorNon-inhibitor0.9355
CYP450 3A4 inhibitorNon-inhibitor0.8601
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9305
Ames testNon AMES toxic0.6828
CarcinogenicityNon-carcinogens0.9133
BiodegradationNot ready biodegradable0.8219
Rat acute toxicity2.7335 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8508
hERG inhibition (predictor II)Non-inhibitor0.5553
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50. [PubMed:9523819]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Basta SJ, Savarese JJ, Ali HH, Embree PB, Schwartz AF, Rudd GD, Wastila WB: Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant. Anesthesiology. 1988 Oct;69(4):478-86. [PubMed:2972233]
  2. Dresner DL, Basta SJ, Ali HH, Schwartz AF, Embree PB, Wargin WA, Lai AA, Brady KA, Savarese JJ: Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. Anesth Analg. 1990 Nov;71(5):498-502. [PubMed:2145783]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:32